8.71
0.09 (1.04%)
| Previous Close | 8.62 |
| Open | 8.62 |
| Volume | 625,128 |
| Avg. Volume (3M) | 2,750,140 |
| Market Cap | 608,080,768 |
| Price / Sales | 7.27 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Operating Margin (TTM) | -276.53% |
| Diluted EPS (TTM) | -5.18 |
| Quarterly Revenue Growth (YOY) | 1,391.60% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | -282.68 M |
| Levered Free Cash Flow (TTM) | -201.84 M |
| Return on Assets (TTM) | -55.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Phathom Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.80 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.28% |
| % Held by Institutions | 84.77% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BREEDLOVE ROBERT CHARLES | - | 12.34 | -461 | -5,689 |
| Aggregate Net Quantity | -461 | |||
| Aggregate Net Value ($) | -5,689 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.34 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BREEDLOVE ROBERT CHARLES | Officer | 05 Sep 2025 | Sell (-) | 461 | 12.34 | 5,689 |
| Date | Type | Details |
|---|---|---|
| 25 Aug 2025 | Announcement | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 20 Aug 2025 | Announcement | Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing |
| 07 Aug 2025 | Announcement | Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates |
| 28 Jul 2025 | Announcement | Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 |
| 23 Jun 2025 | Announcement | Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary |
| 23 Jun 2025 | Announcement | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 16 Jun 2025 | Announcement | Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |